To test whether two sequential BCG-induction courses improves the response of high-risk non-muscle invasive bladder cancer. Achieving a complete response (CR) to BCG is critical to disease-free survival.
Tumor mutation burden (TMB) is an emerging prognostic biomarker of immunotherapy for bladder cancer (BLCA). We aim at investigating radiomic features’ value in predicting the TMB status of BLCA patients.
Christopher Wallis: Hello, and thank you for joining us for this UroToday Journal Club. Today, we’re discussing a recent publication entitled Molecular imaging and biochemical response assessment after a single cycle of 225 Actinium PSMA-617 and 177 Lutetium PSMA-617 tandem therapy in mCRPC patients who have progressed on 177 Lutetium PSMA-617 monotherapy. I’m Chris Wallace, Fellow […]
Chris Wallis: Hello, and thank you for joining us for our UroToday journal club. Today, we’re discussing an important and recent publication in European Urology entitled, Is Prostate Cancer-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-Effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial. I’m Chris Wallis, a fellow in urologic oncology at […]
© European Union, [2021] – Source: European Parliament On Thursday 15 July, Véronique Trillet-Lenoir (FR), lead rapporteur for the European Parliament’s Beating Cancer Committee, presented her draft report on the European Commission’s Beating Cancer Plan to the other members of the Committee. The European Association of Urology (EAU) has used this as an opportunity to […]
In 2012, the United States Preventative Services Task Force (USPSTF) formally recommended against all prostate-specific antigen (PSA) screening for prostate cancer. Our goal was to characterize PSA screening trends in the Veterans Health Administration (VA) before and after the USPSTF recommendation and to determine if PSA screening was more likely to be ordered based on […]
Epithelial-myoepithelial carcinoma (EMC) of the penis is a rare malignant tumor which has not previously been described in the literature. Genetic associations exist in EMC that could potentially help guide early diagnosis and treatment of this type of penile cancer.
The majority of patients with testicular germ cell tumors (GCTs) can be cured with cisplatin-based chemotherapy. However, for a subset of patients present with cisplatin-refractory disease, which confers a poor prognosis, the treatment options are limited.
Indigenous people experience higher rates of end-stage renal disease as well as negative predictive factors that undermine kidney transplantation (KT) success. Despite these inequalities, data suggest that short-term outcomes are comparable to those of other groups, but few studies have examined this effect in the Northern Great Plains (NGP) region.
With the expansion in cross-sectional imaging over the past few decades, there has been an increase in the number of incidentally detected renal masses and an increase in the incidence of renal cell carcinomas (RCCs).
